Intestinal farnesoid X receptor (FXR) antagonists have been proven to be efficacious in ameliorating metabolic diseases, particularly for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.